SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened activity driven by a reported domestic chip manufacturing partnership with Apple, a catalyst that has revitalized the stock's turnaround narrative. Community discussion is polarized between optimistic investors betting on long-term structural re-rating and skeptics who view the price action as an overextended pump fueled by political headlines rather than new information.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing significant retail and institutional interest as investors anticipate a major 52-week clinical data readout for sonelokimab in hidradenitis suppurativa. Community discussion is heavily focused on the potential for a transformative valuation re-rating, with many actively debating the probability of an M&A catalyst following recent clinical progress and best-in-class performance expectations.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp. is generating significant buzz as investors anticipate upcoming data center lease announcements, with recent federal grid rulings further validating the company's shift toward power-intensive AI infrastructure. The stock's performance on the TSX exchange while US markets were closed has fueled community speculation regarding institutional pre-positioning ahead of Russell 3000 inclusion and potential hyperscaler partnerships.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently a focal point for intense debate, as investors weigh the potential for a blow-off top against the aggressive, liquidity-driven momentum in AI-related hardware. Community discourse is sharply divided between bulls capitalizing on institutional buying of every dip and skeptical bears pointing to overextended technicals and macro uncertainties surrounding geopolitical stability.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as market participants speculate on potential integration with Elon Musk's broader business ecosystem, including recent developments surrounding SpaceX. The community remains deeply divided, with some investors aggressively accumulating positions in anticipation of a potential bull run, while others dismiss the asset as a speculative meme coin.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to heightened community speculation surrounding the pending 80th event milestone for the REGAL Phase 3 trial and anticipation of a potential buyout. Investors are actively debating the impact of elevated short interest, high borrow rates, and the company's progress toward late-stage commercialization.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as market participants react to the collapse of weekend peace negotiations between the U.S. and Iran, with traders bracing for a potential impact on oil prices and overall market sentiment. Community discussions are split between those anticipating a sharp pullback due to escalating geopolitical tensions and those betting that institutional buyers will once again defend support levels to initiate another tactical pump.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a breakthrough AI-powered imaging partnership with Midjourney, which is fueling massive daily volume and intense short-squeeze speculation. While bulls are highlighting the potential for significant long-term growth driven by new semiconductor chip licensing, skeptics are expressing concerns over high volatility, potential dilution, and the company's path to consistent profitability.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is currently trending as investors speculate on potential M&A activity, with community discourse fueled by reports that the company has hired advisors to explore strategic alternatives, including a possible acquisition. While some market participants are bullish on the stock as a potential buyout target, others remain cautious, citing significant debt levels and the broader headwinds facing the airline sector from elevated fuel costs.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the recent commercial launch of NEREUS for motion sickness while speculating on a potential buyout by major pharmaceutical firms like Eli Lilly. Community sentiment remains focused on the company's GLP-1 adjunct pipeline and recent drug approvals, despite ongoing frustration regarding price volatility and management's confrontational regulatory strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
